[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"participants-who-received-an-allogeneic-chimeric-antigen-receptor-t-cell-product-pbcar-in-a-precision-biosciences-inc-clinical-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:participants-who-received-an-allogeneic-chimeric-antigen-receptor-t-cell-product-pbcar-in-a-precision-biosciences-inc-clinical-study":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100502451","long-term-follow-up-of-study-participants-who-received-an-allogeneic-chimeric-antigen-receptor-t-cell-product-in-an-imugene-ltd-clinical-study-100502451",false,"NCT05822427","Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study","Inclusion Criteria:\n\n* Receipt of at least 1 dose of azer-cel in an Imugene clinical study.\n* A signed informed consent form (ICF).\n* Willingness and ability to adhere to the study schedule and all other protocol requirements.\n\nExclusion Criteria:\n\n* No unique exclusion criteria apply to this study.","ALL","18 Years",{"count":18,"type":19},75,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to collect information on the long-term safety of study participants who received an Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Product in an Imugene Clinical Study. The main questions it aims to answer are:\n\n* What are the frequency, severity, duration, and outcome of clinically significant Clinical Events of Interest (CEI)?\n* What is the duration of response and overall survival time after taking an allogeneic CAR T-Cell product on an Imugene clinical study?\n\nParticipants will have a yearly visit either face to face or remotely for up to 15 years to check for CEI.",[23],"Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study",[25,26],"Allogeneic chimeric antigen receptor (CAR) T cell products","azer-cel","RECRUITING","2025-05-11",{"date":30,"type":31},"2025-05-14","ACTUAL",{"date":33,"type":31},"2020-08-25",{"date":35,"type":19},"2039-12",{"name":37,"class":38},"Imugene Limited","INDUSTRY"]